These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8034842)

  • 1. Allergic reactions to polidocanol for vein sclerosis. Two case reports.
    Feied CF; Jackson JJ; Bren TS; Bond OB; Fernando CE; Young VC; Hashemiyoon RB
    J Dermatol Surg Oncol; 1994 Jul; 20(7):466-8. PubMed ID: 8034842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indications for the sclerosing agent polidocanol (aetoxisclerol dexo, aethoxisklerol kreussler).
    Guex JJ
    J Dermatol Surg Oncol; 1993 Oct; 19(10):959-61. PubMed ID: 8408916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence.
    Todd KL; Wright DI;
    Phlebology; 2014 Oct; 29(9):608-18. PubMed ID: 23864535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urticaria induced by Etoxisclerol (polidocanol).
    Henriquez-Santana A; Fernandez-Guarino M; González de Olano D; Gonzalez-Cervera J; Huertas-Barbudo B; Aldanondo I
    J Eur Acad Dermatol Venereol; 2008 Feb; 22(2):261-2. PubMed ID: 18211438
    [No Abstract]   [Full Text] [Related]  

  • 5. Sclerotherapy: a study comparing polidocanol in foam and liquid form.
    Uncu H
    Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Embolia cutis medicamentosa of the foot after sclerotherapy.
    Geukens J; Rabe E; Bieber T
    Eur J Dermatol; 1999 Mar; 9(2):132-3. PubMed ID: 10066964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polidocanol (aethoxysklerol) for sclerotherapy of superficial venules and telangiectasias.
    Goldman PM
    J Dermatol Surg Oncol; 1989 Feb; 15(2):204-9. PubMed ID: 2644330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anaphylaxis following use of polidocanol].
    Stricker BH; van Oijen JA; Kroon C; Ovink AH
    Ned Tijdschr Geneeskd; 1990 Feb; 134(5):240-2. PubMed ID: 2304580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polidocanol: the perfect "solution".
    Weiss RA
    J Dermatol Surg Oncol; 1994 Jul; 20(7):465. PubMed ID: 8034841
    [No Abstract]   [Full Text] [Related]  

  • 10. Localized retiform purpura after accidental intra-arterial injection of polidocanol.
    Yébenes M; Gilaberte M; Toll A; Barranco C; Pujol RM
    Acta Derm Venereol; 2005; 85(4):372-3. PubMed ID: 16191871
    [No Abstract]   [Full Text] [Related]  

  • 11. The Australian polidocanol (aethoxysklerol) study. Results at 2 years.
    Conrad P; Malouf GM; Stacey MC
    Dermatol Surg; 1995 Apr; 21(4):334-6; discussion 337-8. PubMed ID: 7728486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerotherapy of varicose veins with polidocanol based on the guidelines of the German Society of Phlebology.
    Rabe E; Pannier F
    Dermatol Surg; 2010 Jun; 36 Suppl 2():968-75. PubMed ID: 20590702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The French polidocanol study on long-term side effects: a survey covering 3,357 patient years.
    Guex JJ; Schliephake DE; Otto J; Mako S; Allaert FA
    Dermatol Surg; 2010 Jun; 36 Suppl 2():993-1003. PubMed ID: 20590706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of Varithena® (polidocanol endovenous microfoam 1%) for symptomatic, visible varicose veins with saphenofemoral junction incompetence.
    Gibson K; Kabnick L;
    Phlebology; 2017 Apr; 32(3):185-193. PubMed ID: 27013511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.
    Rabe E; Otto J; Schliephake D; Pannier F
    Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durability of treatment effect with polidocanol endovenous microfoam on varicose vein symptoms and appearance (VANISH-2).
    Todd KL; Wright DI;
    J Vasc Surg Venous Lymphat Disord; 2015 Jul; 3(3):258-264.e1. PubMed ID: 26992303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up.
    Moreno-Moraga J; Smarandache A; Pascu ML; Royo J; Trelles MA
    Phlebology; 2014 Dec; 29(10):658-66. PubMed ID: 23989971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible ischaemic neurological deficit after sclerotherapy of varicose veins.
    Van der Plas JP; Lambers JC; Van Wersch JW; Koehler PJ
    Lancet; 1994 Feb; 343(8894):428. PubMed ID: 7905592
    [No Abstract]   [Full Text] [Related]  

  • 19. Indications for the sclerosing agent polidocanol.
    Duffy DM
    J Dermatol Surg Oncol; 1994 Jul; 20(7):494-5. PubMed ID: 7661903
    [No Abstract]   [Full Text] [Related]  

  • 20. Sclerotherapy: review of results and complications in 200 patients.
    Puissegur Lupo ML
    J Dermatol Surg Oncol; 1989 Feb; 15(2):214-9. PubMed ID: 2915088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.